A real-world clinical study on the efficacy and safety of tenofovir amibufenamide for the treatment of patients with chronic hepatitis B

Objective To analyze the efficacy and safety of tenofovir amibufenamide for the treatment of patients with chronic hepatitis B in the real world and to provide a reference for the subsequent selection of antiviral treatment for chronic hepatitis B. Method A total of 186 cases of patients with chronic hepatitis B were collected. Among them, 93 patients had been treated with TMF for 48 weeks, and 93 patients had been treated with TDF for 48 weeks. The primary indicator was the virological response rate. The secondary indicators included the normalization rate of serum alanine aminotransferase (ALT) levels and the changes in the levels of hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), creatinine, uric acid, calcium ions and phosphate. Results There was no significant difference in the virological response rate between the TMF group and the TDF group at 48 weeks of treatment ( P > 0.05). There was a significant difference in the normalization rate of ALT (83.31% vs. 52.01%) after 48 weeks of treatment between the TMF and TDF groups, respectively ( P < 0.05). Likewise, there was a significant difference in the HBeAg seroconversion rate (19.35% vs. 7.53%) after 48 weeks of treatment between the TMF and TDF groups, respectively ( P < 0.05). There was a significant difference in serum creatinine levels (77.36 ± 16.87 µmol/L vs. 83.13 ± 17.23 µmol/L) between the TMF and TDF groups after 48 weeks of treatment ( P < 0.05). However, there were no significant changes in the levels of uric acid, calcium ions or phosphate. Conclusion Tenofovir amibufenamide is effective and safe for the treatment of patients with chronic hepatitis B. Compared with tenofovir disoproxil fumarate, it has a higher ALT normalization rate and a higher HBeAg seroconversion rate.